

JHL DOSES FIRST PATIENT IN JHL1101 PHASE I EUROPEAN TRIAL

29 March 2017 – JHL Biotech Inc. (Stock Code: 6540.TWO) today announced that the first patient has been dosed in the company's Phase I clinical trial of JHL1101 (a proposed rituximab biosimilar) in rheumatoid arthritis patients.

The randomised, double-blind, parallel group, multicentre study will compare the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and efficacy of JHL1101 versus EU sourced MabThera® in anti-tumor necrosis factor (TNF) inadequate responder patients with moderate to severe rheumatoid arthritis. The study is designed to enroll 150 patients from the European Union, Russia, Taiwan, and Ukraine.

According to Racho Jordanov, JHL's co-founder and CEO, "I am happy to announce formal commencement of the Phase I trial of JHL1101. JHL is committed to increasing access to exceptional quality biologics, and our Phase I European clinical trial will provide a means to prove the safety, efficacy, and high quality of JHL1101."

喜康生物相似藥 JHL1101 於第一個病人用藥進行歐盟第一期臨床實驗

2017年3月29日喜康生物（股票代號：6540.TWO）今天宣布，喜康生物申請中的生物相似藥 JHL1101（利妥昔單體抗體生物相似藥）已在第一類風濕關節炎患者上用藥，這是在歐盟第一期臨床實驗的重要里程碑。

相關實驗將通過多中心隨機，雙盲，平行對照臨床試驗來比較 JHL1101 和取自歐洲的原研藥美羅華兩者針對患中等到嚴重類風濕性關節炎並對抗腫瘤壞死因子（TNF）缺乏反應的患者在藥代動力學，藥效，免疫原性，安全性及療效上的表現。計劃將有 150 位來自歐盟國家，蘇聯，台灣以及烏克蘭的患者將參與該項臨床實驗。

喜康生物共同創辦人暨執行長喬石瑞先生表示：“我很高興能宣布 JHL1101 在歐盟正式開展第一期臨床實驗。喜康生物致力於普及化高品質的生物製劑，喜康 JHL1101 在歐盟第一期臨床實驗將證明這款藥的安全，藥效及高品質特性。”

END

About JHL Biotech

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech's mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. For more information, please visit www.jhlbiotech.com.

關於喜康生技

喜康生技醫藥公司（興櫃：6540）是一家由具有醫藥研發和製造的深厚經驗的資深團隊創立的新創公司。喜康投資者包括世界級領先創投基金，私募基金，銀行凱鵬華康，紅杉，Biomark Capital，麥頓投資，富達，以及中華開發銀行。喜康生技的任務是提供世界高品質和價格合理的生物藥品。喜康生技專注於研發新蛋白質藥品以及生物類似喜康生技具有兩座達到中歐美 ICH，cGMP 標準的世界級藥廠。喜康的台灣研發基地專注於生物類似藥臨床前早期研發工作。喜康的武漢藥廠會用於大批量製造。喜康有獨特的能力可提供自有生物藥品的製造並可執行戰略夥伴的工藝研發以及製造專案。如需了解更多信息，請訪問 www.jhlbiotech.com.

Media Contact:

Gregory Manker

JHL Biotech

Strategic Planning and Business Development, Associate

gmanker@jhlbiotech.com

聯繫人：

孟軒

喜康生技股份有限責任公司

戰略與企業擴展部，助理

gmanker@jhlbiotech.com